Tebipenem pivoxil, the first oral carbapenem for complicated urinary tract infections: a review

Nivasini Natarajan Thangam; Kala Paneerselvam

doi:10.18203/2319-2003.ijbcp20263800

Authors

Nivasini Natarajan Thangam Department of Pharmacology, PSP Medical College Hospital and Research Institute, Oragadam, Kancheepuram, Chennai, Tamil Nadu, India
Kala Paneerselvam Department of Pharmacology, PSP Medical College Hospital and Research Institute, Oragadam, Kancheepuram, Chennai, Tamil Nadu, India https://orcid.org/0000-0002-9694-3024

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20263800

Keywords:

Complicated urinary tract infection, Tebipenem pivoxil, Oral carbapenem, Pyelonephritis, Antimicrobial resistance, Carbapenem-sparing therapy, Antimicrobial stewardship, Gut microbiota, Metallo-β-lactamase

Abstract

Complicated urinary tract infections (cUTIs) are increasingly difficult to manage because emerging antimicrobial resistance limits conventional oral treatment options. Tebipenem pivoxil hydrobromide is an orally administered prodrug of tebipenem. It was recently approved by the US FDA in June 2026. It represents the first oral carbapenem available for adults with cUTI, including pyelonephritis, caused by specified susceptible organisms when limited or no alternative oral options exist. The pivotal PIVOT-PO trial demonstrated non-inferiority of oral tebipenem pivoxil 600 mg every 6 hours to intravenous imipenem-cilastatin for 7–10 days in hospitalised adults with cUTI or pyelonephritis, building on earlier non-inferiority evidence against intravenous ertapenem from the ADAPT-PO programme. After summarising the pharmacology, microbiology, pharmacokinetics, dosing, efficacy, safety and gut-microbiome data underlying the United States approval, this review offers a critical appraisal of where tebipenem pivoxil fits among the several new oral agents recently introduced for urinary tract infection, and considers its relevance to antimicrobial-resistance settings such as India, where carbapenem resistance among Enterobacterales is substantial and driven predominantly by metallo-β-lactamases against which no currently available carbapenem, including tebipenem, retains activity. The clinical value of tebipenem is therefore best understood not as a universal substitute for intravenous carbapenems or for narrower-spectrum oral agents, but as an option for carefully selected patients needing carbapenem-level activity and suitable for oral therapy, guided by local susceptibility data, renal dose adjustments, awareness of carnitine depletion and valproic acid interactions, and proper antimicrobial stewardship.

References

McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016;22(11):946-57.

World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022. Available from: https://www.who.int/publications/i/item/9789240062702 Accessed on 10 July 2026.

Bonkat G, Pickard R, Bartoletti R, Bruyère F, Geerlings SE, Wagenlehner F, et al. EAU guidelines on urological infections. Arnhem: European Association of Urology; 2017. Available from: https://d56bochluxqnz.cloudfront.net/documents/EAU-Guidelines-Urological-infections-2017.pdf Accessed on 10 July 2026.

Chopra T, Tillotson G, Donald A. The changing picture of community acquired urinary tract infections in the US: a daunting prospect. Expert Rev Anti Infect Ther. 2026;24(9):845-53.

Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan AM, et al. Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. N Engl J Med. 2022;386(14):1327-38.

Sodhi V, Kronsberg KA, Clark M, Cho JC. Tebipenem pivoxil hydrobromide-no PICC, no problem! Pharmacotherapy. 2021;41(9):748-61.

US Food and Drug Administration. Utebzi (tebipenem pivoxil) tablets, for oral use: full prescribing information. Reference ID 5818121. Revised June 2026.

Gupta VK, Maier G, Gasink L, Ek A, Fudeman M, Srivastava P, et al. Absorption, metabolism, and excretion of [14C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy male subjects. Antimicrob Agents Chemother. 2023;67(4):e0150922.

Wiesner A, Zagrodzki P, Paśko P. Do dietary interventions exert clinically important effects on the bioavailability of β-lactam antibiotics? A systematic review with meta-analyses. J Antimicrob Chemother. 2024;79(4):722-57.

Patel G, Rodvold KA, Gupta VK, Bruss J, Gasink L, Bajraktari F, et al. Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2022;66(5):e0240721.

Patel G, Gupta VK, Gasink L, Bajraktari F, Lei Y, Jain A, et al. Effect of an antacid (aluminum hydroxide/magnesium hydroxide/simethicone) or a proton pump inhibitor (omeprazole) on the pharmacokinetics of tebipenem pivoxil hydrobromide (TBP-PI-HBr) in healthy adult subjects. Antimicrob Agents Chemother. 2023;67(4):e0149522.

Abouelhassan Y, Fratoni AJ, Shepard AK, Nicolau DP, Asempa TE. Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. J Antimicrob Chemother. 2022;78(1):296-301.

Rodvold KA, Gotfried MH, Gupta V, Ek A, Srivastava P, Talley A, et al. Plasma and intrapulmonary concentrations of tebipenem following oral administration of tebipenem pivoxil hydrobromide to healthy adult subjects. Antimicrob Agents Chemother. 2022;66(7):e0059022.

Fouad A, Quintiliani R, Nicolau DP, Asempa TE. Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. J Antimicrob Chemother. 2022;78(1):205-8.

Melnick D, Talley AK, Gupta VK, Critchley IA, Eckburg PB, Hamed KA, et al. Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2023;67(10):e0053523.

Sun Z, Su L, Cotroneo N, Critchley I, Pucci M, Jain A, et al. Evaluation of tebipenem hydrolysis by β-lactamases prevalent in complicated urinary tract infections. Antimicrob Agents Chemother. 2022;66(5):e0239621.

Becka SA, Zeiser ET, LiPuma JJ, Papp-Wallace KM. The class A β-lactamase produced by Burkholderia species compromises the potency of tebipenem against a panel of isolates from the United States. Antibiotics (Basel). 2022;11(5):674.

Mendes RE, Arends SJR, Streit JM, Critchley I, Cotroneo N, Castanheira M. Contemporary evaluation of tebipenem in vitro activity against Enterobacterales clinical isolates causing urinary tract infections in US medical centers (2019-2020). Microbiol Spectr. 2023;11(1):e0205722.

Ito M, Yasuda M, Hayashi M, Tanaka K. Antimicrobial activity of tebipenem to Escherichia coli isolates from outpatients with complicated urinary tract infections. J Infect Chemother. 2025;31(6):102712.

ClinicalTrials.gov. A study of oral tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenous imipenem-cilastatin in participants with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) (PIVOT-PO). Bethesda (MD): National Library of Medicine (US); 2023. Available from: https://clinicaltrials.gov/study/NCT06059846 Accessed on 10 July 2026.

Bhavnani SM, Hammel JP, Rubino CM, Talley AK, Eckburg PB, Liolios K, et al. Evaluation of factors predictive of efficacy among patients with complicated urinary tract infection and/or acute pyelonephritis. Open Forum Infect Dis. 2024;11(9):ofae375.

Sewunet T, Razavi M, Rosenborg S, Camporeale A, Nowak M, Melnick D, et al. Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial. Lancet Microbe. 2024;5(4):e355-65.

Mojica MF, Hausman BS, Pearlmutter BS, Zink EG, Wilson BM, Villamil V, et al. Impact of tebipenem pivoxil on the intestinal microbiota and on establishment of colonization with carbapenem-resistant Klebsiella pneumoniae in mice. Microbiol Spectr. 2025;13(5):e0234624.

Nuzhat S, Islam MR, Bashar SJ, Das S, Amin R, Qadri F, et al. Pharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh. Sci Rep. 2024;14:31965.

Nuzhat S, Islam MR, Das S, Bashar SJ, Pavlinac PB, Arnold SL, et al. Tebipenem pivoxil as an alternative to ceftriaxone for clinically non-responding children with shigellosis: a randomised non-inferiority trial protocol. BMJ Open. 2025;15(2):e088449.

Zhang CX, Nuzhat S, Islam MR, Bashar SJ, Das S, Amin R, et al. Population pharmacokinetic and pharmacodynamic prediction for tebipenem pivoxil treatment of pediatric shigellosis. Clin Transl Sci. 2026;19(1):e70453.

Fernández Álvaro E, Voong Vinh P, de Cozar C, Willé DR, Urones B, Cortés A, et al. The repurposing of tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp. eLife. 2022;11:e69798.

Negatu DA, González Del Río R, Cacho-Izquierdo M, Barros-Aguirre D, Lelievre J, Rullas J, et al. Activity of oral tebipenem-avibactam in a mouse model of Mycobacterium abscessus lung infection. Antimicrob Agents Chemother. 2023;67(2):e0145922.

Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis. JAMA. 2022;328(13):1304-14.

Ramaraj A, Nivasini NT, Balaji V, James J, Varadarajan S. Cefepime-enmetazobactam: a novel β-lactam/β-lactamase inhibitor combination for complicated urinary tract infections. Int J Basic Clin Pharmacol. 2025;14(4):590-6.

Hamed KA, Salama AH, Moeck G, Wagenlehner FM. Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistance. Expert Rev Anti Infect Ther. 2026;24(9):827-44.

Guerriero S, Matteini E, Gross MM, Gavi F, Tamburrini E, Murri R, et al. Complicated urinary tract infections: an update of new and developing antibiotics. Expert Opin Pharmacother. 2025;26(2):167-77.

Broughton E, Bektas M, Colosia A, Kuper K, Fernandez MM, Al-Taie A, et al. A systematic literature review of the epidemiology of complicated urinary tract infection. Infect Dis Ther. 2025;14(6):1157-81.

Rodriguez-Monguio R, Seoane-Vazquez E, Powers JH 3rd. Evidentiary standards for newly approved antibiotics for uncomplicated urinary tract infections. Antibiotics (Basel). 2026;15(3):238.

Khan Z, Bose P, Kumari S, Rangnekar A, Panwalkar N, Desikan P. Carbapenem resistance and associated resistance genes in Enterobacteriaceae and non-Enterobacteriaceae in India: a systematic review and meta-analysis. Indian J Med Res. 2026;163(4):505-19.

Rajni E, Bairwa K, Galav H, Upadhyaya H, Gajjar D. An update on carbapenem-resistant Enterobacterales: a prospective study from Western India. J Postgrad Med. 2025;71(2):61-7.

Wagenlehner F, Rico Caballero V, Maheshwari V, Biswas A, Saini P, Quevedo J, et al. Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis. J Comp Eff Res. 2025;14(3):e240214.